References
- Spencer JA, Shutt DP, Moser SK, et al. Distinguishing viruses responsible for influenza-like illness. J Theor Biol. 2022;545:111145. doi: 10.1016/j.jtbi.2022.111145.
- Health U. Is it influenza or an influenza-like illness?. 2020.
- CDC. US influenza surveillance system: purpose and methods. FluView Website (downloaded October 29. https://wwwcdc gov/flu/weekly/overview htm. 2020
- C M. Tripledemic: what happens when flu, RSV, and COVID-19 cases collide?. Yale Medicine. 2023.
- Dadashi M, Khaleghnejad S, Abedi Elkhichi P, et al. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:681469. doi: 10.3389/fmed.2021.681469.
- Kim D, Quinn J, Pinsky B, et al. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085–2086. doi: 10.1001/jama.2020.6266.
- Reina J, Dueñas J. Respiratory co-infections between influenza viruses and respiratory syncytial virus (2014-2017). Coinfecciones respiratorias entre los virus gripales y el virus respiratorio sincitial (2014-2017). An Pediatr (Engl Ed). 2019;90(2):118–119. doi: 10.1016/j.anpedi.2018.02.011.
- 2022-2023 U.S. Flu season: preliminary in-season burden estimates. Centers for Disease Control and Prevention. 2023. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm.
- CDC. Estimated COVID-19 burden. 2022.
- JHU. Covid 19 dashboard by the center for systems science and engineering (CSSSE) at Johns Hopkins University (JHU). 2023.
- RSV Surveillance & Research. Centers for Disease Control and Prevention. 2023. https://www.cdc.gov/rsv/research/index.html.
- Tong S, Amand C, Kieffer A, et al. Incidence of respiratory syncytial virus related health care utilization in the United States. J Glob Health. 2020;10(2):020422. doi: 10.7189/jogh.10.020422.
- Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging. 2005;22(7):577–587. doi: 10.2165/00002512-200522070-00004.
- Childs A, Zullo AR, Joyce NR, et al. The burden of respiratory infections among older adults in long-term care: a systematic review. BMC Geriatr. 2019;19(1):210. doi: 10.1186/s12877-019-1236-6.
- Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus—United States, 2017-2023. https://www.cdc.gov/mmwr/volumes/72/wr/mm7214a1.htm.
- Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the seasonality of respiratory syncytial virus in the United States: the impact of increased molecular testing. J Infect Dis. 2017;216(3):345–355. doi: 10.1093/infdis/jix275.
- Mirsaeidi M, Motahari H, Khamesi MT, et al. Climate change and respiratory infections. Ann Am Thorac Soc. 2016;13(8):1223–1230. doi: 10.1513/AnnalsATS.201511-729PS.
- Zhang N, Wang L, Deng X, et al. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020;92(4):408–417. doi: 10.1002/jmv.25674.
- Price CP. Point of care testing. BMJ. 2001;322(7297):1285–1288. doi: 10.1136/bmj.322.7297.1285.
- Callum J, McDiarmid D, Chew R. The impact of rapid PCR testing for viral respiratory infections on acute admissions from the emergency department and inpatient length of stay. J Acute Med. 2022;12(3):96–104. doi: 10.6705/j.jacme.202209_12(3).0002.
- Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Ann Intern Med. 2017;167(6):394–409. doi: 10.7326/m17-0848.
- Vos LM, Bruning AHL, Reitsma JB, et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis. 2019;69(7):1243–1253. doi: 10.1093/cid/ciz056.
- Boukli N, Flamand C, Chea KL, et al. One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance. Front Med (Lausanne). 2023;10:1161268. doi: 10.3389/fmed.2023.1161268.
- Cepheid. Xpert® xpress SARS-CoV-2/flu/RSV. Package insert. 2021.
- Alshaikh FS, Godman B, Sindi ON, et al. Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2022;17(8):e0272375. doi: 10.1371/journal.pone.0272375.
- Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2022;27(1):33–45. doi: 10.1136/bmjebm-2020-111511.
- Steponavičienė A, Burokienė S, Ivaškevičienė I, Stacevičienė I, Vaičiūnienė D, Jankauskienė A. Influenza and Respiratory Syncytial Virus Infections in Pediatric Patients during the COVID-19 Pandemic: A Single-Center Experience. Children (Basel). 2023;10(1).
- Liu YL, Xie TA, Lin GL, et al. Diagnostic accuracy of xpert xpress flu/RSV for the detection of influenza and respiratory syncytial viruses. Jpn J Infect Dis. 2022;75(2):183–191. doi: 10.7883/yoken.JJID.2020.987.
- Gentilotti E, De Nardo P, Cremonini E, et al. Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(1):13–22. doi: 10.1016/j.cmi.2021.09.025.
- Lee J, Song J-U. Diagnostic accuracy of the cepheid xpert xpress and the abbott ID NOW assay for rapid detection of SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2021;93(7):4523–4531. doi: 10.1002/jmv.26994.
- Brümmer LE, Katzenschlager S, McGrath S, et al. Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta-regression analyzing influencing factors. PLoS Med. 2022;19(5):e1004011-e1004011. doi: 10.1371/journal.pmed.1004011.
- CDC. Disease burden of flu. Center for disease control and prevention. 2022.
- COVID-19 Testing: what You Need to Know. Centers for Disease Control and Prevention. 2023. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html.
- Table 2a. Therapeutic Management of Nonhospitalized Adults With COVID-19 With Mild to Moderate COVID-19 Who Do Not Require Supplemental Oxygen. https://www.covid19treatmentguidelines.nih.gov/tables/management-of-nonhospitalized-adults-summary/.
- Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1–e47. doi: 10.1093/cid/ciy866.
- Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969–1975. doi: 10.1002/lary.27852.
- Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18(1):318. doi: 10.1186/s12913-018-3139-1.
- Storms AD, Chen J, Jackson LA, et al. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017;17(1):208. doi: 10.1186/s12890-017-0552-x.
- Misurski DA, Lipson DA, Changolkar AK. Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care. 2011;17(9):601–608.
- Kuitunen I, Renko M. The effect of rapid point-of-care respiratory pathogen testing on antibiotic prescriptions in acute infections—a systematic review and meta-analysis of randomized controlled trials. Open Forum Infect Dis. 2023;10(9):ofad443. doi: 10.1093/ofid/ofad443.
- CDC Flu Burden. https://www.cdc.gov/flu/about/burden/index.html.
- Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14):1667–1672. doi: 10.1001/archinte.163.14.1667.
- Choi Y, Hill-Ricciuti A, Branche AR, et al. Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019. Influenza Other Respir Viruses. 2022;16(1):151–158. doi: 10.1111/irv.12912.
- Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. doi: 10.7326/m22-2141.
- McLaughlin JM, Khan F, Schmitt HJ, et al. Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and Meta-Analysis. J Infect Dis. 2022;225(6):1100–1111. doi: 10.1093/infdis/jiaa752.
- Ohsfeldt RL, Choong CK, Mc Collam PL, et al. Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther. 2021;38(11):5557–5595. doi: 10.1007/s12325-021-01887-4.
- Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza a virus and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487–1498. doi: 10.1097/CCM.0b013e3182416f23.
- Taylor G, Abdesselam K, Pelude L, et al. Epidemiological features of influenza in Canadian adult intensive care unit patients. Epidemiol Infect. 2016;144(4):741–750. doi: 10.1017/s0950268815002113.
- Tristram DA, Welliver RC. Respiratory syncytial virus. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious diseases. Philadelphia, PA: Churchill Livingstone; 2003. p. 1140–1148.
- Clinical Laboratory Fee Schedule. 2023. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.
- CMS Physician Fee Schedule. 2023. https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched.
- Fingar K, Liang L, Stocks C. Inpatient hospital stays and emergency department visits involving influenza, 2006-2016. 2023. https://hcup-us.ahrq.gov/reports/statbriefs/sb253-Influenza-Hospitalizations-ED-Visits-2006-2016.jsp.
- Rae M, Claxton G, Kurani N, et al. Potential costs of COVID-19 treatment for people with employer coverage. 2023. https://www.healthsystemtracker.org/brief/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage/#Average%20total%20cost%20of%20treatment%20for%20pneumonia%20among%20large%20employer%20plans,%20by%20level%20of%20complexity,%202018.
- Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group. JAMA. 2000;283(8):1016–1024. doi: 10.1001/jama.283.8.1016.
- Tisdell CA. Economic, social and political issues raised by the COVID-19 pandemic. Econ Anal Policy. 2020;68:17–28. doi: 10.1016/j.eap.2020.08.002.
- You JHS, Tam LP, Lee NLS. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS One. 2017;12(7):e0182091. doi: 10.1371/journal.pone.0182091.
- Rahmanzadeh F, Malekpour N, Faramarzi A, et al. Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran. BMC Health Serv Res. 2023;23(1):861. doi: 10.1186/s12913-023-09868-9.
- Lai X, Rong H, Ma X, et al. The economic burden of influenza-like illness among children, chronic disease patients, and the elderly in China: a national Cross-Sectional survey. Int J Environ Res Public Health. 2021;18(12):6277. doi: 10.3390/ijerph18126277.
- de Courville C, Cadarette SM, Wissinger E, et al. The economic burden of influenza among adults aged 18 to 64: a systematic literature review. Influenza Other Respir Viruses. 2022;16(3):376–385. doi: 10.1111/irv.12963.
- Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine. 2002;20(19–20):2562–2578. doi: 10.1016/S0264-410X(02)00154-8.
- Whitsel LP, Ajenikoko F, Chase PJ, et al. Public policy for healthy living: how COVID-19 has changed the landscape. Prog Cardiovasc Dis. 2023;76:49–56. doi: 10.1016/j.pcad.2023.01.002.
- Rezapour A, Souresrafil A, Peighambari MM, et al. Economic evaluation of programs against COVID-19: a systematic review. Int J Surg. 2021;85:10–18. doi: 10.1016/j.ijsu.2020.11.015.
- Heyward G, Silver M. WHO ends global health emergency declaration for COVID-19. Washington, DC: NPR. 2023.
- Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12(3):171–174. doi: 10.4103/picr.picr_62_21.
- Woloshin S, Dewitt B, Krishnamurti T, et al. Assessing how consumers interpret and act on results from at-home COVID-19 self-test kits: a randomized clinical trial. JAMA Intern Med. 2022;182(3):332–341. doi: 10.1001/jamainternmed.2021.8075.